Overall survival benefits of cancer drugs in the WHO Model List of Essential Medicines, 2015–2021

INTRODUCTION: We examined overall survival (OS) benefits for targeted cancer drugs recommended for List of Essential Medicines (EMLs) since 2015. We assessed consistency of decisions in 2019 and 2021 with more specific criteria: OS benefit >4 months and high scores on European Society for Medical...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Yue, Naci, Huseyin, Chen, Dingyi, Bai, Lin, Shi, Luwen, Guan, Xiaodong, Wagner, Anita Katharina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10546158/
https://www.ncbi.nlm.nih.gov/pubmed/37775106
http://dx.doi.org/10.1136/bmjgh-2023-012899

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10546158/
https://www.ncbi.nlm.nih.gov/pubmed/37775106
http://dx.doi.org/10.1136/bmjgh-2023-012899

Ejemplares similares